摘要
目的：通过对仿制药与原研药的比价的实证研究，探讨其管理策略。方法：采用2014年上海医院购药信息系统的数据。获取276对仿制药及其对应原研药的配对样本，把配对样本的价格转换成可比价格进行比较。结果：仿制药与原研药的全部比价在0．01～1．41之间，均值为0．54±0．26，均值的95％置信区间为0．51～0．57，第一四分位数为0．34，中位数为0．57，第三四分位数为0．73。结论：对仿制药与原研药价格管理策略的建议是把比价的第一和第三四分位数之间的区间作为过渡性合理区间，将来结合仿制药质量一致性评价结果，引导仿制药与原研药的比价向更加合理的区间移动，最终基本实现由市场决定仿制药与原研药的比价。同时，要出台鼓励使用仿制药的配套措施。
Objective： To explore the management strategies of price ratios of generics and originators through the empirical study. Methods： 276 paired samples were selected from Shanghai Hospital Purchasing Drug Information System（HPDIS） 2014. The prices of paired samples were converted into comparable prices. Results： The price ratios of generics and originators varied from 0.01 to 1.41, the average was 0.54±0.26, the 95% confidence interval was 0.51 -0.57, the first quartile was 0.34, the median was 0.57, the third quartile was 0.73. Conclusion： The suggestions on the management strategies of price ratios of generics and originators were taking the interval of first to third quartile of price ratios as the transitional reasonable interval, leading the ratios move into more reasonable interval in consideration of the results of quality consistency assessment for generics in the future, ultimately achieving the goal of determining the ratios basically hy the market. Meanwhile, the supporting measures to encourage the use of generics were needed.
出处
《中国卫生经济》
北大核心
2016年第10期69-72,共4页
Chinese Health Economics
关键词
仿制药
原研药
比价
管理策略
generics
originators
price ratio
management strategy
